IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines
about
Interactions between Autophagy and Inhibitory CytokinesInterleukin-35: Expanding Its Job ProfileFrom IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokinesInterleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 Pathway.The modulation of endoplasmic reticulum stress by chemical chaperone upregulates immune negative cytokine IL-35 in apolipoprotein E-deficient miceIncreased plasma concentrations of interleukin 35 in patients with coronary artery disease.The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease.Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases.Immunosuppressive/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction--a novel mechanism for maintaining vascular functionTumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesisEpigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cellsGastric epithelial expression of IL-12 cytokine family in Helicobacter pylori infection in human: is it head or tail of the coin?Interleukin 35 is an independent prognostic factor and a therapeutic target for nasopharyngeal carcinoma.Association between serum interleukin-35 levels and severity of acute pancreatitis.Elevated serum interleukin-35 levels correlate with poor prognosis in patients with clear cell renal cell carcinomaExpression of Epstein-Barr virus-induced gene 3 in cervical cancer: Association with clinicopathological parameters and prognosis.Analysis for Carom complex, signaling and function by database mining.Metabolic Diseases Downregulate the Majority of Histone Modification Enzymes, Making a Few Upregulated Enzymes Novel Therapeutic Targets--"Sand Out and Gold Stays".Interleukin-17A Promotes Aortic Endothelial Cell Activation via Transcriptionally and Post-translationally Activating p38 Mitogen-activated Protein Kinase (MAPK) Pathway.Inflammatory Response to Lipopolysaccharide on the Ocular Surface in a Murine Dry Eye Model.Identification of novel pretranslational regulatory mechanisms for NF-κB activation.Assessing the role of IL-35 in colorectal cancer progression and prognosis.IL-35 improves Treg-mediated immune suppression in atherosclerotic miceAge-related changes in microRNA levels in serumMitochondrial ROS, uncoupled from ATP synthesis, determine endothelial activation for both physiological recruitment of patrolling cells and pathological recruitment of inflammatory cells.Interleukin 35 Polymorphisms Are Associated with Decreased Risk of Premature Coronary Artery Disease, Metabolic Parameters, and IL-35 Levels: The Genetics of Atherosclerotic Disease (GEA) Study.Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3.Thrombus leukocytes exhibit more endothelial cell-specific angiogenic markers than peripheral blood leukocytes do in acute coronary syndrome patients, suggesting a possibility of trans-differentiation: a comprehensive database mining studyInterleukin 35: a key mediator of suppression and the propagation of infectious tolerance.Bioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents.Interleukin-12 family cytokines and sarcoidosis.IL-35: a potential therapeutic target for controlling hepatitis B virus infection.The Role of PPAR Gamma in Systemic Sclerosis.Immunoregulatory Pathways Involved in Inflammatory Bowel Disease.Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy.Pathological conditions re-shape physiological Tregs into pathological Tregs.Epstein-Barr virus-induced gene 3 (EBI3) can mediate IL-6 trans-signaling.IL-35 Suppresses Lipopolysaccharide-Induced Airway Eosinophilia in EBI3-Deficient Mice.IL-35, as a newly proposed homeostasis-associated molecular pattern, plays three major functions including anti-inflammatory initiator, effector, and blocker in cardiovascular diseases.Lysophospholipid Receptors, as Novel Conditional Danger Receptors and Homeostatic Receptors Modulate Inflammation-Novel Paradigm and Therapeutic Potential
P2860
Q26745577-A8E57468-C5E9-4603-837C-7C60CE020755Q26829619-D70C2B4A-75C6-4317-97A3-2ACBA95CF9D8Q27008912-CFC90CFD-B269-43DC-84F8-8643F15E2181Q27312371-EEB8DBFF-F1D8-48C7-A5EE-DF7D84028A04Q28539349-D8AED70C-5F3A-4484-A3C0-D0E16DBBE433Q33904487-97C121E4-15EF-4A19-BFA8-C6CADF9251FCQ34119277-231D3B7F-33E2-48B8-8279-E6ABDF82A54CQ34534000-CF19B273-3B8D-4589-96B5-A4B0171E2490Q34538722-F0893258-A03E-4B38-9907-7693C3E010B3Q34647584-C007FF7B-B30D-4785-B1B8-CE0900D50661Q34656908-9575EA41-440D-4848-8EC2-0EA101BD8648Q34999507-550438CF-CD50-4423-AFF4-13A20C3B8094Q35648984-409CF877-D940-4210-B8DB-EB598CDE534DQ35870800-003B0540-C12E-4FD1-A4C2-F63E67892760Q36412024-F77101D1-6165-4980-A7C5-719F30BBC9C1Q36502703-B7A4945D-5644-4552-940D-B052BA76A5C9Q36604293-38DE94E0-8C93-435E-A1B2-F9EFD7E1EE27Q36619589-01386AEB-4A7F-4395-BF85-541257CED112Q36650270-EDBDF0AA-1D3C-4D35-B17F-1B63B1BCE63AQ36872927-022DBE70-3851-45F5-B1AC-7113D631BF62Q36890591-5F6AF629-4A7F-4ABC-BC9F-86465048CC97Q37137999-C0F35745-E416-4C83-A6A2-8193CB6ED8DEQ37289372-9A860290-69D0-4A14-9524-3CEA97FEE2E7Q37338097-8BAF28C4-11EA-4521-9D9F-391AA7128C8EQ37679976-EE914303-5E82-4594-8F8E-119B28F0E369Q37685707-3EABF7B6-6796-4CE7-B88A-C9DED948BE53Q37687332-536F1775-C477-491B-B2BB-245C8A365413Q37719815-0058010A-C146-46CC-9E9C-728309D217ABQ38154886-575E74FB-C423-4D1E-B97C-91CA9D628FA8Q38191014-0FDB51AD-A69A-4CCE-A1E5-E0B0290F9EA9Q38266881-C7851591-603E-4667-B0A6-1E5F7380A70BQ38283391-EA137625-8B35-4709-BB9F-C99018FFF5DDQ38524619-73C1AD5D-1EDD-4677-AE2E-191DFE06C35FQ38537820-D89F55AE-6495-4271-BAD6-14B6910669A0Q38650594-BDA31D24-6E74-4C5B-ACF2-51F0ADD48CB2Q38654764-98BAC056-1CCA-42C1-B11A-E59A88834E2DQ38712876-C528C8A0-A861-4E9B-8135-A80A381BBF55Q38729193-388F7898-8D1F-4CE5-8F84-BE4CFBC09E17Q39396961-FEA21DC0-DEB4-4653-A021-44CBC2249930Q39732801-6F286ADA-2EBB-4F47-B5BA-4934AE0B16CB
P2860
IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@ast
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@en
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@en-gb
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@nl
type
label
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@ast
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@en
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@en-gb
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@nl
altLabel
IL-35 Is a Novel Responsive An ...... ng Anti-inflammatory Cytokines
@en
prefLabel
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@ast
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@en
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@en-gb
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@nl
P2093
P2860
P3181
P1433
P1476
IL-35 is a novel responsive an ...... ng anti-inflammatory cytokines
@en
P2093
Andrew Frisch
Anthony Virtue
Imani Hodge
Jietang Mai
Stefanie Gutchigian
Xiao-Feng Yang
Xiaohua Jiang
Xiaojin Sha
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0033628
P407
P50
P577
2012-01-01T00:00:00Z